Other investigations also revealed a connection between ICB resistance and the dangling activation of CD8+ Trm cells in malignant tissues.[74, 75] Our results suggested that ZNF683+ CD8+ T cells resident in RCC modelled by the limited tumor recognition restrained by MARCO response poorly to ICB therapies. Here, CD8A is linked to neoplasm.